Retension Pharmaceuticals, Inc.
small molecule therapeutics for hypertension and cardiovascular disease
Follows are private to you and power your alerts
Updated · retensionpharmaceuticals.com
- Sector
- Biotech
- Headquarters
- MCLEAN, VA
- Founded
- 2023
- Latest Form D
- $12.3M, May 2025
- Total capital
- $18.1M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $18.1M
- 2 Form D · last May 2025
- 18 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 5 pending · first 2025
- Rank in peer group#481 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$12.3M
- Private capital raisedForm D · SEC · 1st filing$5.8M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#481 · top 33%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Donald OldsDirectorNamed in SEC Form D filings
- Eric KellerExecutive Officer, DirectorNamed in SEC Form D filings
- Michael BerendtDirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 6- PendingCrystalline FormUSPTOApplication 19077760
- GrantedCRYSTALLINE FORMS OF 4-ETHOXY-N-(2-METHOXYETHYL)-N-METHYL-3-(5-METHYL-4-OXO-7-PROPYL-3,4-DIHYDROIMIDAZO[5,1-f][1,2,4]TRIAZIN-2-YL)BENZENESULFONAMIDEUSPTOUS 12,258,350
- PendingCrystalline FormUSPTOApplication PCTUS2025055203
Show all 6 patent records
- Crystalline FormMay 14, 2026 · Application 19077760Pending
- CRYSTALLINE FORMS OF 4-ETHOXY-N-(2-METHOXYETHYL)-N-METHYL-3-(5-METHYL-4-OXO-7-PROPYL-3,4-DIHYDROIMIDAZO[5,1-f][1,2,4]TRIAZIN-2-YL)BENZENESULFONAMIDEMar 25, 2025 · US 12,258,350Granted
- Crystalline FormApplication PCTUS2025055203Pending
- Combination TherapyApplication PCTUS2025055152Pending
- Crystalline Forms of 4-Ethoxy-N-(2-Methoxyethyl)-N-Methyl-3-(5-Methyl-4-Oxo-7-Propyl-3,4-Dihydroimidazo[5,1-f][1,2,4]Triazin-2-YL)BenzenesulfonamideApplication 19052679Pending
- Combination TherapyApplication 63720592Pending
Related companies, and why
- Cellective BioTherapy, Inc.Similar federal contract value in Biotech · null in contracts
- Elion, Inc.Similar federal contract value in Biotech · null in contracts
- Firefly BioSimilar federal contract value in Biotech · null in contracts
- Clade & Co., Inc.Similar federal contract value in Biotech · null in contracts
- AbbraTech Holdings LLCSimilar federal contract value in Biotech · null in contracts
- Phycin, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .